Emilie has six years of experience in rare disease market access. Areas of expertise include strategy development, policy (including revision of the General Pharmaceutical Legislation), access in low- and middle-income countries and value communication. Prior to joining Dolon, Emilie obtained a BSc in Biology (with minors in Global Health and Math) in the US, and a MSc in Health Policy from the LSE and LSHTM